“We can’t take the orphan drug revolution for granted.“ Biorasi’s Few & Far Between Podcast welcomes Jim Geraghty, author and biotech industry veteran, to discuss the necessity and viability of orphan and rare disease research - for both patients and VC investors alike.
"Try to find the people who have a really strong background in regulatory science, who really understand the fundamentals, and who you believe can...
Tune in for today's full episode of Few & Far Between. Episode 9 features Biorasi's Becky Knockemus, Zogenix, Inc.'s Dawn Blessing, and J. Michael...
"So we built the seatbelts before the car, so to speak, wherein we did a project to figure out ways to biocontain these organisms....